惠升生物以贯穿组学为平台，以高通量低成本的技术为支撑，服务于大科学和大民生，建立行业标准，让全人类都能掌握自己的健康。惠升生物运用强大的测序平台、信息技术平台及生物信息分析技术，依靠高通量测序领域和临床基因检测领域内顶尖的的技术团队，率先将人类基因组测序技术实践于临床检测，并与领域内知名的301医院建立了合作关系。惠升生物为人类提供贯穿整个生命周期的健康服务，涉及遗传病、血液病、病原微生物、肿瘤等领域，在向重大疫病筛查与诊断领域不断深入的同时，并主要应用于肿瘤临床治疗，实现基于个体健康差异的精准医疗服务。
PhytoDerProtein Corp makes multi-omics as a platform and makes high-throughput low-cost technology as the support to serve the big science and the people's livelihood, and establish of industry standards, so that all mankind can master their own health. PhytoDerProtein Corp uses the powerful sequencing platform, information technology platform and bioinformatics analysis technology, relying on high-throughput sequencing and clinical gene detection in the field of top technical team, and it is the first to make human genome sequencing technology practice in clinical testing, and it has established cooperative relations with the well-known 301 hospitals in this filed.PhytoDerProtein Corp provide human with health services throughout the life cycle, involving genetic diseases, blood diseases, pathogenic microorganisms, tumors and other fields. It is deepening in in the field of screening and diagnosing major diseases. At the same time, it is mainly used in clinical treatment of cancer to achieve precision medical services based on individual health differences.
运用先进的基因检测技术，同时运用蛋白质组、代谢组等多组学整合为基础的生命组学，为基因组提供了更接近表型的验证和解释，为癌症早期发现、良恶性诊断、分型和个性化用药、疗效监测和预后判断等提供了更精确、更可靠的信息，使精准医学更加精准。
Use advanced genetic testing technology, while use the life group based on proteomics, metabolic groups and other multi-group integration to provide genome with validation and interpretation closer to the phenotype. It provides more accurate and more reliable information to early detection of cancer, benign and malignant diagnosis, classification and personalized medication, efficacy monitoring and prognosis to make precision medicine more accurate.
生命活动由众多基因、蛋白质、以及小分子代谢产物来共同承担。基因水平信息反映的是疾病发生的概率（即可能性）。蛋白质组学直接检测基因产物、呈现翻译后修饰与可变剪切，为基因组数据提供验证与解读。代谢组处于基因调控网络和蛋白质作用网络的下游，提供生物学的终端信息。发现、验证疾病标志物，用于更精准的疾病早期诊断、肿瘤良恶性判断、疾病疗效与预后监测。
惠升生物与301医院肿瘤合作，通过抽5ml静脉血检测全身16种微量突变因素和外周血DNA，可以提前5-7年预测体内患18中癌症的风险，是目前全世界最先进的技术，比日本的PET-CT更先进了3-5年，从而大大提早了肿瘤发现的时间，为早期干预和早期治疗赢得了宝贵时间。癌变组织可筛查的最小直径，国内普通医院为1cm，而北京301医院率先做到了行业国内最高精度8mm。
Life activities are undertaken by a large number of genes, proteins, and small molecule metabolites. Genetic level information reflects the probability of disease (the likelihood). Proteomics direct detects gene products and shows post-translational modification and variable shear to provide validation and interpretation of genomic data. The metabolic group is located downstream of the gene regulatory network and the protein-mediated network, providing biologic terminal information. It is the identification of finding and proving. It can be used for more accurate early diagnosis of the disease, diagnosing early malignant tumors, disease efficacy and prognosis monitoring.
PhytoDerProtein Corp cooperates with 301 hospital tumor by pumping 5ml venous blood to detect 16 kinds of mutations in the body and peripheral blood DNA, which can predict the risk of 18 cancers in patients 5 to 7 years in advance. It is the world's most advanced technology. It is more advanced than Japan's PET-CT 3 to 5 years, which greatly advances the time of tumor discovery, and wins a valuable time for early intervention and early treatment. The smallest diameter cancer tissue can be screened is 1cm in the domestic general hospital, while in the Beijing 301 Hospital, the it is 8mm which is the industry's highest precision.
惠升生物分析个体的家族遗传病史，发病情况，分析个体可能罹患的疾病，特别是重大恶性疾病，比如肿瘤。同时，整合基因组、转录组、蛋白质组，在蛋白质及后修饰层面对癌症分型，为个性化治疗提供新思路。
基因检测是目前癌症精准分型与精准用药的主要方法，但是基因与生命活动的最终执行者——蛋白质之间仍然存在较大差异，难以直接反映生命变化。蛋白质组学直接检测基因产物、呈现翻译后修饰与可变剪切，为基因组数据提供验证与解读。TCGA与CPTAC合作即分别在基因组和蛋白质组层面对肿瘤样本进行大规模分析，获得大数据，挖掘癌症机理，实现精准医学（Cell, 2015, 163: 202; Nature, 2016, 534: 55; Cell, 2016, 166: 755.）。
Husheng biology analyzes the genetic history of the family, morbidity, and the disease individual may suffer from, especially the major malignant diseases, such as cancer. At the same time, integrates genome, transcriptome and proteome, and classifies cancer in the protein and post-modification level to provide new ideas for individual treatment.
Genetic testing is the main method of accurate classification and accurate medication of cancer, but there is still a big difference between the gene and the ultimate performer-protein of life activities, and it is difficult to directly reflect the change of life. Proteomics directly detects gene products, and shows post-translational modification and variable shear to provide validation and interpretation for the genomic data. TCGA cooperates with CPTAC to do large-scale analysis, gain large data, mining cancer mechanism and achieve precision medicine. （Cell, 2015, 163: 202; Nature, 2016, 534: 55; Cell, 2016, 166: 755.）.
惠升生物研究蛋白质、后修饰、代谢物，筛选免疫反应、信号通路中的关键分子，发现药物治疗新靶标。绝大多数的药物治疗靶标都是蛋白质。研究表明，人体中全部的药物靶点蛋白超过1万种，而目前发现的靶点仅有500种左右。疾病的精准治疗亟待大量全新治疗靶标的发现与使用。
2015年启动的人类免疫肽组学计划(HIPP)，即致力于使用蛋白质组学手段，收集并测定人细胞表面MHC-I与MHC-II（或称HLA）呈现的所有肽段序列，更透彻地理解免疫系统，指导并加快下一代疫苗的开发和自身免疫病、传染性疾病、癌症免疫治疗方案的开发。
惠升生物基于植物瞬时表达平台核心技术，目前已成功表达多种单克隆抗体，并即将进入临床试验阶段。 肿瘤个体化治疗: 评估检测者患病风险，并为肿瘤患者制定有效的个体化治疗方案。采用成熟的基因检测技术，结合生物信息分析，分析患者的遗传变异信息，预测癌症患病风险，指导受检者制定个性化的保健方案；另外可以为肿瘤患者提供全方位的用药指导，实现肿瘤的个性化治疗。该项目具有专业性强、更全面、准确性高等特点，有助于改善临床肿瘤的诊断和治疗方式。
PhytoDerProtein Corp researches protein, post-modification, metabolite, screening immune response, signaling pathways in key molecules, and finds drug treatment of new targets. The vast majority of drug treatment targets are proteins. Studies have shown that all drug target proteins in body are more than 10,000, but only about 500 kinds pf targets are found in the current. The precise treatment of the disease requires a large number of new treatment targets are discovered and used.
The HIPP program, launched in 2015, is dedicated to the collection and determination of all peptide sequences on MHC-I and MHC-II (or HLA) on human cell surface using proteomics To understand the immune system, to guide and accelerate the development of next-generation vaccines and autoimmune diseases, infectious diseases, cancer immunotherapy program development.
PhytoDerProtein Corp has successfully expressed a variety of monoclonal antibodies based on the core technology of plant transient expression platform, and will soon enter the clinical trial stage. Tumor individualized therapy: Assess the risk of the investigator and make an effective individualized regimen for cancer patients. Use mature genetic testing technology, combine with bioinformatics analysis and analyze genetic variation information of patients to predict the risk of cancer to guide the subjects to develop personalized health care program; in additions, it also can cancer provide a full range of medication guidance to patients to achieve the personalized treatment of tumor. The project is strong professional, more comprehensive, high accuracy, and it is help to improve the diagnosis and treatment of clinical tumors.
数字化地存储与管理生命是未来的趋势。样本的数字化是实现多组学层次的生命健康大数据，构建数字样本库和疾病数据库的利器。惠升生物通过数千至数万例癌症病人样本的收集和DIA-MS采集，构建数字样本库；通过大数据挖掘深层次的疾病特征，构建疾病数据库，为精准地癌症诊断、分型、治疗奠定基础。
Digitally restoring and managing life is the future trend. The digitization of the samples is a good tool for achieving large numbers of life and health data and building a digital sample library and a disease database. PhytoDerProtein Corp builds digital sample library by the collection of tens of millions of cases of cancer patients and DIA-MS; deeply excavates the characteristics of disease by the large data and builds disease database to lay the foundation of accurate cancer diagnosis, classification and treatment.
